GlassScriptPhysician profile
Mikio Tachibana
NPI 1598721227
$5,509.79
in general payments reported to CMS, 2019-2025
16 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,092 · 2020: $278 · 2021: $145 · 2022: $682 · 2023: $634 · 2024: $1,112 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,973.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $1,241.04 | 2019-2020 | |
| Amgen INC. | $801.09 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $418.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Inari Medical, INC. | $176.73 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.84 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $148.76 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $121.49 | 2022 | |
| Vifor Pharma, INC. | $113.08 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.66 | 2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $65.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.74 | 2019-2020 | |
| Medtronic Minimed, INC. | $43.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.67 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $19.71 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.24 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikio Tachibana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.